Date of event
Tuesday, July 26, 2022 - 1:00 pm -
Tuesday, July 26, 2022 - 2:00 pm
Continuing Education Credits
None
Add to Calendar 2022-07-26 13:00:00 2022-07-26 14:00:00 Webinar: Noninvasive Diagnostic Tools and Treatment Paradigms for NAFLD and NASH: What’s New? AASLD alonzo.tolver@boldrstrategy.com America/New_York public

Content Contributor

Nonalcoholic Fatty Liver Disease SIG

Presenters

  • Arun Sanyal, MD, FAASLD
  • Stephen A. Harrison, MD

Moderator

  • Somaya A. M. Albhaisi, MBBCh, MD
  • Mazen Noureddin, MD

Details

Although most patients with NAFLD and NASH have traditionally been diagnosed and managed by hepatologists, the recent availability of noninvasive diagnostic procedures is expanding the role of other health care professionals likely to see patients with these conditions. Early recognition and intervention are key to improving clinical outcomes and reducing the economic and health care burden of NAFLD. There is no FDA approved drugs for NAFLD/NASH to date, nonetheless, pharmacological therapy for NASH is an area of significant ongoing investigation. This webinar will discuss the noninvasive diagnostic tools and emerging treatments/therapeutic approaches of NAFLD/NASH. The latest updates will be discussed in an interactive discussion.


 

Presenter Bios

Arun J. Sanyal, MD, FAASLD

Arun J. Sanyal, MD, FAASLD is a Professor of Medicine, Physiology and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University (VCU) Medical Center in Richmond, Virginia. Dr. Sanyal also serves as Chairman of the NIH NASH Clinical Research Network, the NIMBLE consortium and the Liver Forum for NASH and fibrosis. His research interests include all aspects of NAFLD and NASH as well as complications of end stage liver disease. He has served as a member of numerous advisory boards to pharmaceutical companies and the liver center at Yale University.  He chaired the hepatobiliary pathophysiology study section of the NIH and was a founding member of the Hepatology committee of the American Board of Internal Medicine.  He has also served as Secretary as well as President of the American Association for Study of Liver Diseases. 

Dr. Sanyal has authored more than 350 articles in such publications as Cell Metabolism, Nature Medicine, New England Journal of Medicine, Lancet, Gastroenterology, Hepatology, and the Journal of Infectious Diseases and has a H-index of 102.  He has been continuously funded by the NIH since 1995 and is the principal investigator of four active NIH grants.  He is the recipient of the Distinguished Mentorship Award from the American Gastroenterological Association and the Distinguished Scientific Achievement Award from the American Liver Foundation in 2017 and the Distinguished Achievement Award from the AASLD in 2018.  

Photo of Dr. Arun J. Sanyal


 

Stephen A. Harrison, MD

Stephen Harrison, MD, FACP, FAASLD earned his medical degree from the University of Mississippi School of Medicine. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University. He is board certified in both Internal Medicine and Gastroenterology.

Dr. Harrison is a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford. He is internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 200 peer reviewed publications in these fields. Dr Harrison currently serves as the Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research in San Antonio, Texas.

Photo of Dr. Stephen A. Harrison


 

Moderator Bios

Somaya A. M. Albhaisi, MBBCh, MD

Somaya Albhaisi, MBBCh, MD is an Assistant Professor of Medicine in the Department of Internal Medicine at the Virginia Commonwealth University School of Medicine in Richmond, VA, USA. Dr. Albhaisi’s research focuses on the epidemiology, prevention, and treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) cirrhosis.

Dr. Albhaisi is currently serving in the Steering Committee of the Liver Transplantation Special Interest Group for the American Association for the Study of Liver Diseases (AASLD) and is a member of the Journals Publications Committee for the AASLD. She has served in the AASLD’s Taxonomy Task force and the Education Subcommittee of the NAFLD Special Interest Group. She is a peer-reviewer for several medical journals including Clinical Liver Disease, Frontiers, and Annals of Internal Medicine. She is currently involved in multiple studies and clinical trials in patients with NAFLD, NASH cirrhosis and metabolic syndrome, and is conducting several studies targeting outcomes in pregnant women with NAFLD. She is mentoring high school, undergraduate and medical students in the U.S. and overseas.

Photo of Dr. Somaya A. M. Albhaisi


 

Mazen Noureddin, MD, MHSc

Mazen Noureddin, MD, MHSc is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center (currently ranked #2 in GI and GI surgery per US News). His focus is on clinical and translational research in the area of NAFLD/NASH. Dr. Noureddin has conducted more than 35 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, trainset elastography, and magnetic resonance imaging techniques.

Dr. Noureddin has published in all these areas. He has given invited lectures on NAFLD/NASH at national and international society meetings and serves on several steering committees/advisory boards for industry. He is the chair of the AASLD NASH special interest group education sub-committee and serves on the editorial board for the journals “Clinical Gastroenterology and Hepatology (CGH)” and “Gastroenterology”. He is funded by the National Cancer Institute.

Photo of Dr. Mazen Noureddin